Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio

Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.

Supernus stock in focus as Sage agrees to buy (SAGE:NASDAQ)

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading...

Supernus Pharmaceuticals picks up embattled Sage Therapeutics

Open the article to view the coverage from Mugglehead Magazine

Supernus to Acquire Sage Therapeutics in $795M Deal

In a bold bid to dominate the neuropsychiatric treatment space, Supernus Pharmaceuticals Inc. announced Monday that it will acquire Sage Therapeutics Inc. in a transaction valued at up to $795 million, striking a deal that could reshape the pharmaceutical landscape in central nervous system (CNS) care. Backed by Saul Ewing LLP, Supernus will pay $8.50 per share in cash—a total of $561 million—to purchase Sage, based in Cambridge, Massachusetts. …

Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology

After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.